secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001826667-25-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors
--------------------------------------------------------------------------------

- Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.
- Filing a Form 12b-25 for late 10-K due to errors in stock-based compensation and R&D expense timing.
- Reaffirms 2025 guidance: >50% revenue growth, >20% OpEx reduction, positive EBITDA, positive cash flow H2 2025.
- Cash $8.5M at Dec 31, plus $15M available under $50M OrbiMed credit facility.
- Launched TriNav LV and TriGuide catheters; DELIVER program expanding addressable market to >$1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000024/0001826667-25-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000182666725000024/tlsi-20250327.htm
  HTML page:      https://secwatch.observer/filing/0001826667-25-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer